Sentences with phrase «preidentified tumor antigens»

Another version, the CTC - iChip, rapidly isolates CTCs in a way that does not rely on preidentified tumor antigens, allowing capture of cells with gene expression patterns that may be missed by the antibodies used in the HBCTC - Chip.

One of the 43 began producing a new protein, which the researchers took to be an antibody to the tumor antigen.

The remaining one - third of patients, composing a control group, received injections of their own dendritic cells that were not exposed to tumor antigens.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

He also studies the mechanisms of antigen presentation to T cells, the impact of immunoregulation on tumor antigen - specific responses, and characterization of the tumor - immune microenvironment.

The light - sensitive cells and nanoparticles, called opto - CRAC, were then delivered with the tumor antigen surrogate ovalbumin to mice with melanoma tumors in their lymph nodes to see if an immune response could be activated to target cancer cells.

Dr. Gnjatic's research focuses on human antigen - specific immune responses to tumor antigens, in an attempt to define new targets for the development of cancer immunotherapies, assess the efficacy of these immunotherapies, and learn why they may fail.

Early - stage data suggests the investigative LAMP - Vax technology works by fusing tumor antigens to a cellular protein known as LAMP (Lysosomal - Associated Membrane Protein).

A team led by principal investigator Donald M. O'Rourke, MD, an associate professor of Neurosurgery at Penn, and Marcela Maus, MD, PhD, showed that CART - EGFRvIII cells had an acceptable safety profile, crossed the blood - brain barrier, infiltrated the tumor, and prompted an immune response, resulting in reduction of the EGFRvIII tumor antigen in GBM cells.

In a 2009 paper published in Nature Materials, Mooney demonstrated that this could be achieved by loading a porous scaffold — about the size of a dime — with tumor antigen as well as a combination of biological and chemical components meant to attract and activate dendritic cells.

Singlet oxygen tends to rip apart tumor cells in a manner that exposes many new tumor antigens to immune cells called dendritic cells, which, like police executing a dragnet, grab the antigens and present them to T cells for closer inspection.

The CNIC research team generated cytotoxic memory T cells specifically targeting cancer by using different methods for vaccination with tumor antigens.

Immunity is key to long - term responses Knowing that the immune system is capable of recognizing distinctive features of cancer cells and launching a T cell attack against those tumor antigens, and that checkpoint blockade removes a roadblock to that attack, it's logical that these drugs should work against many tumor types.

Vincent Brichard, Thomas Wölfel, and Thierry Boon identify the first CTL - defined tumor antigen derived from a melanoma differentiation protein, tyrosinase.

High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

(PMID: 15657293) Download PDF Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.

Trajanoski Z, Maccalli C, Mennonna D, Casorati G, Parmiani G, Dellabona P. Somatically mutated tumor antigens in the quest for a more efficacious patient - oriented immunotherapy of cancer.

Lloyd Old, Thierry Boon, and colleagues develop the TNF release assay for mouse systems in which release of TNF by T cells could be used to assess specific T cell recognition, facilitating the cloning of human tumor antigens.

Phosphorylation of Merkel cell polyomavirus large tumor antigen at serine 816 by ATM kinase induces apoptosis in host cells.

Modulation of tumor antigen expression, particularly MHC class I and II is a particularly common component of tumor immune evasion 183.

This has involved preclinical and clinical evaluation in Phase I and Phase I / II studies that have characterized tumor antigen expression and immune responses in patients.

Low frequencies of tumor antigen - specific cells in the peripheral blood has been a limiting factor in treatment.

The infection releases tumor antigens in a way that jump - starts the immune response.»

These are more specific therapies such as monoclonal antibodies and cancer vaccines, which target specific tumor antigens.

She has obtained intramural support through the Vanderbilt Physician Scientist Development (VPSD) Award Program and a Cancer Center Grant Support (CCSG) Award to identify relevant tumor antigens / targets in breast cancer tumor samples.

The specific antigen approach uses selected antigens that are also present in the patient's tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

Treatment with HSV1 - TK is expected to kill transduced brain cells, thus exposing tumor antigen.

There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir - induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.

Tsuji T, Matsuzaki J, Caballero OL, Jungbluth AA, Ritter G, Odunsi K, Old LJ, Gnjatic S. (2012) Heat shock protein 90 - mediated peptide - selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4 + T cells.

Recently she characterized anti-tumor effects of a unique human CD4 + helper T - cell subset that directly recognizes the cytoplasmic tumor antigen, NY - ESO - 1, presented by MHC class II on cancer cells.

This novel vaccine encodes the tumor antigen TERT, which is highly expressed in tumor cells, and is particularly high in tumor samples from patients with mutations in DNA damage repair pathways, such as the BRCA1 / BRCA2 pathway.

First, when GLA is accompanied by a tumor antigen and injected into a patient, the combination is taken up by the DCs and leads to the production and expansion of immune cells called CD4 helper T cells.

In our most advanced ZVex - based product candidate, CMB305, the vector carries the RNA for a tumor antigen called NY - ESO - 1 that is expressed in a wide range of tumors.

Instead of targeting specific tumor antigens, this approach relies on endogenous antigens (including neoantigens) released during tumor lysis by treatments such as chemotherapy or local radiation.

They do, however, play a key role in helping to boost the anti-tumor immune response by: (1) expanding the number and improving the function of existing CTLs that are specific to the same tumor antigen; and (2) providing help to other immune cells, including B lymphocytes that are precursors to antibodies and natural killer (NK) cells that are also important in the overall anti-tumor immune response.

«Some approaches to creating cancer vaccines begin by extracting a patient's own immune cells, priming them with tumor antigens and returning them to the patient, a process that is complex and expensive,» says Mark Poznansky, MD, PhD, director of the MGH Vaccine and Immunotherapy Center and senior author of the report.

Similar to CTLs, these CD4 T cells will be specific to a tumor antigen, but unlike CTLs, they generally can not kill antigen - bearing tumor cells.

This process activates the CD8 T cell and causes it to divide, creating millions of CTLs to kill tumor cells that bear that specific tumor antigen, including neoantigens.

In the experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells» processing and presentation of several different tumor antigens, inducing a number of T - cell - based immune responses.

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

As noted above, existing cancer vaccines that use dendritic cells require extracting cells from a patient's blood, treating them with an engineered protein or nucleic acid that combines tumor antigens with immune - stimulating molecules, and returning the activated dendritic cells to the patient.

Also, CMB305 was well tolerated, and generated a strong and broad anti-NY-ESO-1 immune response in > 50 % of the patients, including evidence of antigen spreading — the induction of an immune response against other tumor antigens not targeted by CMB305.

In addition, because ZVex product candidates have the potential to carry the genetic material of different tumor antigens, as well as immunostimulatory molecules, we can design them to target multiple types of cancers.

Capacity for substantial genetic payload supports multiple tumor antigens or a combination of tumor antigens and other immune stimulatory molecules, such as checkpoint inhibitors.

We believe that when G100 is administered with mechanisms that kill, or lyse, tumor cells (such as radiation), it may cause dendritic cells near the lysed tumor to activate and capture the wide range of released endogenous tumor antigens.

A urine bladder tumor antigen test has been developed and is an excellent screening test to rule out bladder cancer.

These results suggest that tumor antigen loaded CD40 - B may serve as a practical alternative to DC in cell - based vaccine strategies for both dogs and humans with cancer.

Not exact matches

Many tumors release cells with distinctive antigens on their surfaces, and affinity - based techniques can pull these cells out of the blood sample relatively easily.